Personalized therapy for pazopanib by pharmacokinetic analysis in patients with renal cell carcinoma or malignant soft tissue tumor
Not Applicable
- Conditions
- Renal cell carcinoma Malignant soft tissue tumor
- Registration Number
- JPRN-UMIN000034034
- Lead Sponsor
- Tohoku Medical and Pharmaceutical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
1)History of hypersensitivity to pazopanib 2)Pregnant status 3)Lactation status
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To analyze blood concentrations of pazopanib showing side effects and efficacy
- Secondary Outcome Measures
Name Time Method To examine factors that affect the blood concentration of pazopanib